RenovoRx has begun commercialising its RenovoCath device after receiving the first purchase orders for the delivery platform, which was cleared by the Food and Drug Administration (FDA).

Leveraging the patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, the device is intended for blood flow isolation and fluid delivery in the peripheral vascular system.

More than ten medical institutions have initiated purchase order processes for the device.

The company is exploring additional revenue opportunities, either independently or with a commercial partner, to meet the expected demand. The initial market for RenovoCath targets healthcare providers dealing with high unmet needs in various clinical settings.

The company plans to expand applications of its delivery system, potentially increasing the total addressable market.

RenovoRx's commercialisation strategy for RenovoCath was driven by demand from oncology and interventional radiology physicians for improved targeted delivery systems.

The company signed a new work order with Medical Murray to increase RenovoCath production.

RenovoRx CEO Shaun Bagai said: “The progress for RenovoCath procurement by medical institutions across the US, as well as our ability to secure our first purchase orders ahead of internal projections, is a strong indicator of the unmet need and particular value our delivery system offers to the oncology market.

“With RenovoCath being successfully used by clinicians in over 500 procedures as part of clinical trials over the past several years, we made the strategic decision earlier this year to move forward with a direct-to-market commercialisation strategy for RenovoCath.”

In addition, the company is also progressing with its TIGeR-PaC Phase III study, which is assessing the TAMP technology for treating locally advanced pancreatic cancer.

The study aims to demonstrate an overall survival benefit and decreased side effects compared to standard care.